GHK-CU 100mg

Overview

GHK-Cu (glycyl-L-histidyl-L-lysine–copper) is a naturally occurring copper-peptide complex first isolated from human plasma albumin in 1973. It is found endogenously in plasma, saliva, and urine, with concentrations declining from approximately 200 ng/mL at age 20 to 80 ng/mL by age 60. This age-related decline is associated with reduced regenerative capacity. GHK-Cu is among the most extensively researched peptides in regenerative medicine and cosmeceutical science.

Mechanism of Action

GHK-Cu functions as both a signaling peptide and a copper-carrying complex. It stimulates collagen, elastin, and glycosaminoglycan synthesis in dermal fibroblasts, modulates matrix metalloproteinase (MMP) activity to support extracellular matrix remodeling, and promotes angiogenesis via vascular endothelial growth factor (VEGF) signaling. Gene expression studies indicate that GHK influences upward of 30% of human genes, including those related to tissue repair, anti-inflammatory responses, antioxidant defense, and nerve regeneration.

Research and Off-Label Applications

Wound healing and tissue repair, skin anti-aging and collagen stimulation, hair follicle health and scalp circulation, anti-inflammatory and antioxidant activity, and emerging investigation into lung fibrosis, gastrointestinal conditions, and neuroprotection.

Administration

Available as both a topical cosmeceutical ingredient (INCI name: Copper Tripeptide-1) and as a prescription injectable. Topical formulations typically show measurable results within 6–8 weeks. Injectable forms may demonstrate changes within 2–4 weeks.

Potential Adverse Effects

Topical use is generally well tolerated. Injectable use may cause mild injection site reactions. Serious adverse events are rare at cosmetic concentrations. Long-term systemic safety data remains under investigation.